Bahrain Mirror: The National Health Regulatory Authority (NHRA) announced the withdrawal of all forms of Zantac and Apo-Ranitidine from the market as they contain some carcinogenic impurities of NDMA according to the results of laboratory tests.

The Authority has also suspended the importation of all other medicines containing ranitidine until safety and laboratory analysis completed.

NHRA indicated that it is coordinating and liaising with the Saudi Food and Drug Authority FDA to monitor the results of the analysis of the remaining items.

The US Food and Drug Administration has warned of carcinogenic impurities in Zantac, but has not recommended withdrawing it from markets due to fact that they are very small quantities.

Arabic Version